Related references
Note: Only part of the references are listed.Fludarabine, Bortezomib, Myocet (R) and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma
Enrico Orciuolo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia
Agathoclis Agathocleous et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
A. Goy et al.
ANNALS OF ONCOLOGY (2009)
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma
Paul M. Barr et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study
Oliver Weigert et al.
LEUKEMIA & LYMPHOMA (2009)
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster et al.
BLOOD (2008)
Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma
F. Morschhauser et al.
ANNALS OF ONCOLOGY (2007)
A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150
A. Belch et al.
ANNALS OF ONCOLOGY (2007)
Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma
Jose Rodriguez et al.
LEUKEMIA & LYMPHOMA (2007)
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Roswitha Forstpointner et al.
BLOOD (2006)
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
David P. Ryan et al.
CANCER (2006)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study
SR Alberts et al.
ANNALS OF ONCOLOGY (2005)
Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP
DW Thomas et al.
LEUKEMIA & LYMPHOMA (2005)
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
M Dreyling et al.
BLOOD (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
A Goy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Proteasome inhibition as a novel therapeutic target in human cancer
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis
CE Denlinger et al.
ANNALS OF THORACIC SURGERY (2004)
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
R Forstpointner et al.
BLOOD (2004)
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line
MM Mortenson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma
C Dumontet et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Gemcitabine for relapsed or resistant lymphoma
DG Savage et al.
ANNALS OF ONCOLOGY (2000)
Share Paper
